A Transgenic Model Reveals Important Roles for the NF-κB Alternative Pathway (p100/p52) in Mammary Development and Links to Tumorigenesis
A regulated pattern of nuclear factor κB (NF-κB) activation is essential for normal development of the mammary gland. An increase in NF-κB activity has been implicated in breast cancer. We have generated a novel transgenic mouse model to investigate the role of the alternative NF-κB pathway in d...
Gespeichert in:
Veröffentlicht in: | The Journal of biological chemistry 2007-03, Vol.282 (13), p.10028 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | A regulated pattern of nuclear factor κB (NF-κB) activation is essential for normal development of the mammary gland. An increase
in NF-κB activity has been implicated in breast cancer. We have generated a novel transgenic mouse model to investigate the
role of the alternative NF-κB pathway in ductal development and identify possible mediators of tumorigenesis downstream of
p100/p52. By overexpressing the NF-κB p100/p52 subunit in mammary epithelium using the β-lactoglobulin milk protein promoter,
we found that transgene expression resulted in increased overall NF-κB activity during late pregnancy. During pregnancy, p100/p52
expression resulted in delayed ductal development with impaired secondary branching and increased levels of Cyclin D1, matrix
metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), and cyclo-oxygenase-2 (COX-2) in the mammary gland. After
multiple pregnancies the p100 transgenics exhibited a ductal thickening accompanied by small hyperplastic foci. In tumors
from mice expressing the polyoma middle T oncoprotein (PyVT) in the mammary gland, increased levels of p100/p52 were present
at the time of tumor development. These results show that increased p100/p52 disrupts normal ductal development and provides
insight into the mechanism by which this may contribute to human breast cancer. |
---|---|
ISSN: | 0021-9258 1083-351X |
DOI: | 10.1074/jbc.M611300200 |